Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

2.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.

J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

3.

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.

Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL.

Clin Cancer Res. 2006 Apr 15;12(8):2526-37.

4.

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, Zinnack K, Beaudry KR, Manson KH, Lifton MA, Kuroda MJ, Letvin NL, Mazzara GP, Panicali DL.

J Virol. 2005 May;79(10):6554-9.

5.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

6.

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.

Clin Cancer Res. 2003 Aug 1;9(8):2973-80.

7.

Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6).

Ambrose Z, Thompson J, Larsen K, Kuller L, Panicali DL, Clements JD, Agy M, Montefiori DC, Hu SL, Bosch ML.

Virology. 2003 Mar 30;308(1):178-90.

9.

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

Chen JL, Dunbar PR, Gileadi U, J├Ąger E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V.

J Immunol. 2000 Jul 15;165(2):948-55.

10.

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.

Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu SL, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, McClure HM.

Nat Med. 1999 May;5(5):526-34.

PMID:
10229229
11.

Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV.

Fuller DH, Simpson L, Cole KS, Clements JE, Panicali DL, Montelaro RC, Murphey-Corb M, Haynes JR.

Immunol Cell Biol. 1997 Aug;75(4):389-96.

PMID:
9315483
12.

Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.

Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL.

J Infect Dis. 1997 Jul;176(1):118-25.

PMID:
9207357
13.

Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity.

Ferbas J, Kaplan AH, Hausner MA, Hultin LE, Matud JL, Liu Z, Panicali DL, Nerng-Ho H, Detels R, Giorgi JV.

J Infect Dis. 1995 Aug;172(2):329-39.

PMID:
7622874
14.

HIV-1-specific cytotoxic T lymphocyte responses in the first year of life.

Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL.

J Immunol. 1995 Jan 1;154(1):433-43.

PMID:
7995957
15.

Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant.

Newman MJ, Munroe KJ, Anderson CA, Murphy CI, Panicali DL, Seals JR, Wu JY, Wyand MS, Kensil CR.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):853-61.

PMID:
7986590
16.

High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.

Daniel MD, Mazzara GP, Simon MA, Sehgal PK, Kodama T, Panicali DL, Desrosiers RC.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):839-51.

PMID:
7986589
17.

Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses.

Kent SJ, Stallard V, Corey L, Hu SL, Morton WR, Gritz L, Panicali DL, Greenberg PD.

AIDS Res Hum Retroviruses. 1994 May;10(5):551-60.

PMID:
7917517
18.

Immunization with lentivirus-like particles elicits a potent SIV-specific recall cytotoxic T-lymphocyte response in rhesus monkeys.

Shen L, Mazzara GP, DiSciullo SO, Panicali DL, Letvin NL.

AIDS Res Hum Retroviruses. 1993 Feb;9(2):129-32.

PMID:
8384466
19.

Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines.

Panicali DL, Mazzara G, Sullivan JL, Hesselton R, Shen L, Letvin N, Daniel M, Desrosiers R, Stott EJ.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1449. No abstract available.

PMID:
1466979
20.

Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus.

Jenkins S, Gritz L, Fedor CH, O'Neill EM, Cohen LK, Panicali DL.

AIDS Res Hum Retroviruses. 1991 Dec;7(12):991-8.

PMID:
1667477
22.

Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Kestler HW 3rd, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC.

Cell. 1991 May 17;65(4):651-62.

PMID:
2032289
23.

Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.

Shen L, Chen ZW, Miller MD, Stallard V, Mazzara GP, Panicali DL, Letvin NL.

Science. 1991 Apr 19;252(5004):440-3.

PMID:
1708168
24.

Two distinct lymphocyte populations mediate simian immunodeficiency virus envelope-specific target cell lysis.

Yamamoto H, Miller MD, Watkins DI, Snyder GB, Chase NE, Mazzara GP, Gritz L, Panicali DL, Letvin NL.

J Immunol. 1990 Dec 1;145(11):3740-6.

PMID:
2147200
25.

Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity.

Yamamoto H, Miller MD, Tsubota H, Watkins DI, Mazzara GP, Stallard V, Panicali DL, Aldovini A, Young RA, Letvin NL.

J Immunol. 1990 May 1;144(9):3385-91.

PMID:
1691757
26.

Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.

Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, et al.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7147-52.

27.

Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.

McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, Carney WP.

Oncogene. 1989 May;4(5):543-8.

PMID:
2566965
28.

Delineation of the viral products of recombination in vaccinia virus-infected cells.

Spyropoulos DD, Roberts BE, Panicali DL, Cohen LK.

J Virol. 1988 Mar;62(3):1046-54.

29.

Supplemental Content

Loading ...
Support Center